David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
|
|
- Rafe Fowler
- 5 years ago
- Views:
Transcription
1 David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
2 At the conclusion of this program, the audience should ldbe able to: List the new oral anticoagulant medications currently approved or in the approval process by the United States Food and Drug Administration Communicate basic principles i of pharmacokinetics to other healthcare providers Identify appropriate indications for the use of new oral anticoagulant medications Develop patient specific plans utilizing newly approved oral anticoagulant agents for the treatment and prevention of venous thromboembolic events in various patient populations
3 Including warfarin, how many oral anticoagulants are currently FDA approved in the United States? 1. One 2. Two 3. Three 4. Four 5. Five 0% 0% 0% 0% 0% One Two Three Four Five
4 Anticoagulant Medications Heparin Approved by FDA Warfarin Approved by FDA Ximelagatran Research Discontinued Dabigatran Approved by FDA Rivaroxaban Approved by FDA Apixaban to be Voted on by FDA Humans in Space Sputnik iki & 2 Yuri igargarin Orbits Earth Alan Shephard Suborbital Flight Americans Land on the Moon 1 st Flight of Columbia (STS 1) Soviets International ti Deploy Space Station Manned is Inhabited Space Station
5 Vitamin K Antagonists (Warfarin) Vitamin K Dependent Proteins Protein Half-life life (hours) Factor II (Prothrombin Prothrombin) Factor VII 4-6 Factor IX Factor X Protein C 9 Protein S 60 Managing Oral Anticoagulation Therapy. St. Louis, MO: WKH, 2009:
6 Warfarin Pros Experience Inexpensive Reversible Monitoring available Cons Time of onset Frequent monitoring Dosing variability Numerous drug interactions
7 21 st Century New therapies with phase III data Dabigatran Rivaroxaban Apixaban Developing therapies Edoxaban
8 Which of the following best describes your opinion regarding the novel new anticoagulant medications? 1. Warfarin is a an adequate medication with good data so I ll continue to use warfarin. 2. Warfarin has many shortcomings and I would prefer to use newer agents. 3. I m Im still a little hesitant aboutthe the newer agents because I m unfamiliar with them. 4. I prefer the newer agents over warfarin; however, I am concerned about the cost of new agents. 5. I have serious concerns aboutthethe safety of newer anticoagulant medications. 0% 0% 0% 0% 0%
9 Which of the following best describes your current prescribing of dabigatran (Pradaxa )? 1. I routinely prescribe dabigatran. 2. I prescribe dabigatran in a limited and select group of patients. 3. I am very hesitant to prescribe dabigatran. 4. I have never prescribed dabigatran. 0% 0% 0% 0%
10 Part I Clinical Pharmacology Comparison
11 Coagulation Cascade Intrinsic Pathway (PTT) Extrinsic Pathway (PT) XII XI IX XIIa XIa IXa VIIa VII Warfarin Rivaroxan & Apixaban Dabigatran X VIII II Xa Va IIa XIII XIIIa Fibrinogen Fibrin
12 Dabigatran Etexilate (Pradaxa ) (Approved 2010) Direct Thrombin Inhibitor Adverse Effects Competitive Prodrug Hydrolysis GI bleeding Peak effect 1 hr (empty stomach) 2 hr (with food) t½ hours Elimination Renal (> 80%) Monitoring Not routinely required Bleeding GI symptoms (35%) compared d to warfarin Consider with ICH Note rate similar to warfarin in VTE trial Pharmacoth 2008;28(11): Drug Metab Dispos 2008;36(2): Pradaxa PI Revised 8/11.
13 Rivaroxaban (Xarelto ) (FDA Approved 2011) Direct Factor Xa Inhibitor Adverse Events Competitive Peak effect 1 hr (empty stomach) 4 hr (with food) t½ 5 9 hours Metabolism & Elimination CYP3A4/5 & P gp Renal (36 % parent) Biliary fecal l(7% parent) Monitoring Not routinely required Bleeding Liver enzymes elevated less frequently in rivaroxaban groupcompared to enoxaparin GI bleeding compared to warfarin Consider with ICH Note rate similar to warfarin in VTE trial Pharmacoth 2009;29(2): Xarelto PI Revised 7/11.
14 Apixaban (Eliquis ) (Not currently approved by the FDA) Direct Factor Xa Inhibitor Adverse Events Competitive Bleeding Peak effect Nausea 3 4 hrs t½ 8 15 hrs Metabolism & Elimination CYP3A4/5 & P gp Renal (27 % parent) Biliary fecal Additional CYP isozymes Monitoring Not routinely required Eliquis PI (EU) Revised 5/11.
15 Monitoring vs. Measuring
16 Thromb Haemost 2010;103: Measuring Dabigatran
17 Measuring Rivaroxaban & Apixaban The aptt is not sensitive enough for anti Xa agents The PT correlates well with serum concentrations The INR is specific to warfarin and is not accurate for anti Xa agents PT is not sensitive enough to detect C trough Anti Xa Assays Chromagenic anti Xa assays may be useful Different assays vary in sensitivity Must calibrate standard curve based on drug concentration HepTest is not accurate for rivaroxaban (and dlikely l apixaban) Incubation period too long Modified dheptest may be useful lbut no current dt data Ther Drug Monit 2010;32:673 9.
18 Which of the following are significantly affected by moderate/severe renal insufficiency? 1. Apixaban 2. Dabigatran 3. Rivaroxaban 4. Both 2 & 3 5. All of the above 0% 0% 0% 0% 0% Apixaban Dabigatran Rivaroxaban Both 2 & 3 All of the abo...
19 Summary Table Parameter Apixaban Dabigatran Rivaroxaban Target Protein Factor Xa Thrombin (IIa) Factor Xa Pro Drug No Yes (etexilate) No 1 Elimination CYP3A4/P gp Renal CYP3A4/P gp Renal Adjustment Avoid < 15 ml/min 15 29ml/min Avoid < 30 ml/min Avoid < 15 ml/min Drug Drug Interact. CYP3A4/P gp Rifampin (P gp) CYP3A4/P gp Onset of activity 3 4 hrs 1 2 hrs 2 4 hrs t½ 8 15 hrs hrs 5 9hrs Dosing interval Twice daily Twice daily Daily Monitoring tests Anti factor Xa ECT, TT, +/ aptt Anti factor Xa
20 Part II Clinical Utilization
21 What are the current approved indications for dabigatran in the United States? 1. Non valvular Afib 2. Prevention of VTE 3. Treatment of VTE 4. All of the above 0% 0% 0% 0% Non valvular A... Prevention of... Treatment of V... All of the abo...
22 Atrial Fibrillation
23 Dabigatran vs. Warfarin in Atrial Fibrillation (RE LY) >18,000 patients with non valvular Afib Non inferiority design Open lbl label Warfarin vs. dabigatran 110 mg BID & dabigatran 150 mg BID Follow up approximately 2 years INR Time in Therapeutic Range (TTR): 64% New Engl J Med 2009;361:
24 RE LY Patient Population InclusionCriteria Afib in addition to: Hx Stroke/TIA LVEF < 40% NYHA Class II HF Age 75 Age in addition to: DM HTN CAD Exclusion Criteria Severe heart valve disorder Recent stroke CrCl < 30 ml/min Liver disease New Engl J Med 2009;361:
25 RE LY Endpoints Primary Composite: stroke & systemic embolization Secondary/Other Stroke Systemic embolization MI PE TIA Mortality New Engl J Med 2009;361:
26 RE LY Patient Demographics Characteristic i Dbi Dabigatran 110 mg Dbi Dabigatran 150 mg Warfarin Age 71.4 ± ± ±8.6 Male Sex 64.3 % 63.2% 63.3% CHADS 2 Score 2.1 ± ± ±1.1 Prior Stroke or TIA 19.9% 20.3% 19.8% Prior MI 16.8% 16.9% 16.1% 1% Aspirin at baseline 40.0% 38.7% 40.6% VKA at baseline 50.1% 50.2% 48.6% New Engl J Med 2009;361:
27 RE LY Results Event Dbi110 Dabi vs Warf Dbi150 Dabi vs Warf Dbi150 Dabi vs Dbi110 Dabi HR (95% CI) HR (95% CI) HR (95% CI) Efficacy 1 Endpoint* 0.91 ( ) 0.66 ( ) 0.73 ( ) All stroke 0.92 ( ) 0.64 ( ) 0.70 ( ) Ischemic c Stroke 1.11 ( ). 0) 0.76 ( ) 0.98) 0.69 ( ) 0.88) Hemorrhagic Stroke 0.31 ( ) 0.26 ( ) 0.85 ( ) MIpublished 1.35 ( ) 1.38 ( ) 1.02 ( ) MI revised 129( ( ) 127( ( ) Not available All cause mortality 0.91 ( ) 0.88 ( ) 0.97 ( ) Safety Major bleeding 0.80 ( ) 0.93 ( ) 1.16 ( ) GI bleeding 1.10 ( ) 1.50 ( ) 1.36 ( ) All bleeding 078( ( ) 0 091( ( ) 0 116( ( ) 1 IC bleeding 0.31 ( ) 0.40 ( ) 1.32 ( ) New Engl J Med 2009;361: New Engl J Med 2010;363: *Non inferiority margin = 1.46
28 RE LY Summary Dabigatran 110 mg BID vs. warfarin Non Inferior Efficacy Lower major and overall bleeding rates Similar il GI bleeding rates Dabigatran 150 mg BID vs. warfarin Superior efficacy Lower overall bleeding rates Similar major bleeding rates Elevated rates of GI bleeding Both doses showed decreased ICH compared to warfarin (60 70% RRR)
29 Rivaroxaban vs. Warfarin in Atrial Fibrillation (ROCKET AF) >14,000 patients Non valvular Afib High risk of stroke Non inferiority i i design Double blind, double dummy Warfarin vs. rivaroxaban 20 mg daily (CrCl 50 ml/min) 15 mg daily (CrCl ml/min) Follow up approximately 2 years INR Time in Therapeutic Range (TTR): 55% New Engl J Med 2011;365:
30 ROCKET AF Patient Population InclusionCriteria Afib with CHADS 2 Score 2 Exclusion Criteria Severe heart valve disorder Recent stroke CrCl < 30 ml/min Liver disease New Engl J Med 2011;365:
31 ROCKET AF Endpoints Primary Composite: stroke or systemic embolization Secondary/Other Composite: Stroke, systemic embolization, CV death, or MI Individual components New Engl J Med 2011;365:
32 ROCKET AF Patient Demographics Characteristic i Rivaroxaban Warfarin Age Male Sex 60.3% 60.3% CHADS 2 Score 3.5 ± ±0.9 Prior Stroke or TIA 54.9% 54.6% Prior MI 16.6% 6% 18% Aspirin at baseline 36.3% 36.7% VKA at baseline 62.3% 62.5% New Engl J Med 2011;365:
33 Event ROCKET AF Rivaroxaban (% per year) Results Efficacy Warfarin (% per year) HR (95% CI) 1 Endpoint* ( ) All stroke ( ) Ischemic Stroke ( ) Hemorrhagic Stroke ( ) MI ( ( ) 06) All cause mortality ( ) Safety Major bleeding ( ) All bleeding ( ) MajorGI bleeding 3.2(% overall) 2.2(% overall) p < IC bleeding ( ) *Non inferiority margin = 1.46 New Engl J Med 2011;365:
34 ROCKET AF Summary Rivaroxabanvs vs. warfarin Similar bleeding rates Lower ICH rates High risk patient population (Mean CHADS 2 score > 3) TTR 55% New Engl J Med 2011;365:
35 Apixaban vs. Warfarin in Atrial Fibrillation (ARISTOTLE) >18,000 patients with non valvular Afib Non inferiority design Double blind, double dummy Warfarin vs. apixaban 5 mg twice daily 2.5 mg twice daily if: Age 80 Weight 60 kg SCr 1.5 mg/dl Follow up approximately years INR Time in Therapeutic Range (TTR): 62% New Engl J Med 2011;365:
36 InclusionCriteria Afib in addition to: Age 75 years Hx Stroke/TIA HF or LVEF 40% DM ARISTOTLE Patient Population Exclusion Criteria Severe heart valve disorder Recent stroke SCr. > 2.5 mg/dl or CrCl < 25 ml/min THN Liver disease New Engl J Med 2011;365:
37 ARISTOTLE Endpoints Primary Composite: stroke or systemic embolization Secondary/Other All cause mortality MI New Engl J Med 2011;365:
38 ARISTOTLE Patient Demographics Characteristic i Apixaban Warfarin Age Male Sex 64.5% 65.0% CHADS 2 Score 2.1 ± ±1.1 Prior Stroke or TIA 19.2% 19.7% Prior MI 14.5% 13.9% Aspirin at baseline 31.3% 30.5% VKA at baseline 57.1% 57.2% New Engl J Med 2011;365:
39 Event ARISTOTLE Apixaban (% per year) Results Efficacy Warfarin (% per year) HR (95% CI) 1 Endpoint* ( ) All stroke ( ) 0.95) Ischemic Stroke ( ) Hemorrhagic Stroke ( ) MI ( ( ) 17) All cause mortality ( ) Safety Major bleeding ( ) All bleeding ( ) IC bleeding ( ( ) 0 *Non inferiority margin = 1.38 New Engl J Med 2011;365:
40 ARISTOTLE Summary Apixaban vs. warfarin Superior efficacy with apixaban overall mortality with apixaban (NNT = 238) Lower bleeding rates with apixaban Lower ICH rates Apixaban vs. Aspirin 6,000 high risk patients (mean CHADS 2 = 2) Not candidates for warfarin 1 year follow up Superior efficacy to aspirin Similar bleeding (including ICH) rates New Engl J Med 2011;365: New Engl J Med 2011;364:
41 Which of the following have been shown at least as effective as warfarin for the prevention of stroke in patients with ihatrial ilfibrillation? ill i 1. Apixaban 2. Dabigatran 3. Rivaroxaban 4. Both 1 & 2 5. All of the above Apixaban 0% 0% 0% 0% 0% Dabigatran Rivaroxaban Both 1 & 2 All of the abo...
42 Summary of Afib Dt Data Apixaban (ARISTOTLE) Dabigatran (RE LY) Rivaroxaban (ROCKET AF) # Patients > 18,000 > 18,000 > 14,000 Mean CHADS TTR 62% 64% 55% Efficacy vs. VKA Superior Superior 1 Non Inferior Bleeding 2 vs. VKA Decreased Similar Similar Elimination CYP3A4/P gp Renal CYP3A4/P gp/renal 1 Dabigatran 150 mg BID group. 2 Major bleeding per study design.
43 Use of Concomitant Antiplatelet Agents Antiplatelet Agents ARISTOTLE (Apixaban) RELY (Dabigatran) ROCKET AF (Rivaroxaban) ASA < 165 mg/day Yes < 100 mg/day Clopidogrel Yes Yes Yes Combination No Yes No Aspirin Use (%) 31% 40% 36% New Engl J Med 2009;361: New Engl J Med 2011;365: New Engl J Med 2011;365:
44 Treatment of Acute Venous Thromboembolism
45 Both dabigatran and rivaroxaban have been shown to be effective in the treatment of acute VTE. 1. True 2. Fl False 0% 0% True False
46 Dabigatran vs. Warfarin Treatment of VTE (RE COVER) Acute DVT or PE for 6 months Double blind, double dummy, RCT Non inferiority trial > 2,500 patients Treatment UFH or LMWH X 5 days and INR > Then dabigatran 150 mg BID or warfarin Outcomes Efficacy (1 endpoint = VTE or related death) Dabigatran non inferior to warfarin Safety Major bleeding: dabigatran & warfarin had similar rates Overall bleeding: dabigatran had lower rates Conclusions Dabigatran was non inferior to warfarin for the acute treatment of VTE Did use standard bridging regimen for both groups UFH/LMWH Dabigatran (active & placebo) started after therapeutic INR in both groups New Engl J Med 2009;361:
47 Rivaroxaban vs. Warfarin Treatment of VTE (EINSTEIN) Acute DVT for 3, 6, or 12 months Open label, RCT Non inferiority trial > 3,400 patients Treatment Rivaroxaban 15 mg BID X 3 weeks, then 20 mg daily for 3, 6, or 12 mos. (duration determined by MD) Enoxaparin followed by warfarin (INR ) Outcomes Efficacy (1 endpoint = Recurrence of VTE) Rivaroxaban non inferior to warfarin Safety Major bleeding: rivaroxaban & warfarin had similar rates Overall bleeding: rivaroxaban & warfarin had similar rates Conclusions Rivaroxaban was non inferior to warfarin for the acute treatment of DVT Used Rivaroxaban monotherapy compared to standard of care Rivaroxabanbetter better thanplacebo inthe Extension study (EINSTEIN EXT) EXT) PE arm of the study series is still ongoing New Engl J Med 2009;363:
48 Summary of VTE Dt Data 1 Dabigatran (RE COVER) Rivaroxaban (EINSTEIN) # Patients > 2,500 > 3,400 Treatment Duration 6 months 6 months Initial Therapy 2 LMWH Rivaroxaban TTR 60% 58% Efficacy vs. VKA Non Inferior Non Inferior Bleeding vs. VKA Similar Similar VTE Type DVT & PE DVT 1 Apixaban data in VTE are not available, AMPLIFY & AMPLIFY EXT are ongoing. 2 Initial therapy in study group, both studies bridged control group.
49 Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
50 Dabigatran Studied in TKA and THA Compared to enoxaparin (European dosing) 40 mg daily Commonly administered prior to surgery Dabigatran dosed once daily 220 mg & 150 mg evaluated EU labeling is 220 mg daily & adjusted for age and CrCl ½ maintenance dose administered i dpost op day 0 Efficacy Non inferior to European dosing of enoxaparin Inferior to US FDA approved dosing of enoxparin (30 mg SQ q12h) Safety Bleeding rates similar between all groups J Thromb Haemost 2005;3: J Thromb Haemost 2007;5: Lancet 2007;370: J Arthro 2009;24:1 9.
51 Rivaroxaban Studied in TKA and THA Compared to enoxaparin 40 mg SQ daily 30 mg SQ twice daily Rivaroxaban dosed 10 mg once daily Efficacy Superior to enoxaparin at both dosages Safety Similar rates of bleeding compared to enoxaparin New Engl J Med 2008;358: Lancet 2008;372:31 9. N Engl J Med 2008;358: Lancet 2009;373:
52 Apixaban Studied in TKA and THA Compared to enoxaparin 40 mg SQ daily 30 mg SQ twice daily Apixaban dosed 2.5 mg twice daily Efficacy Superior to enoxaparin at 40 mg daily Non inferior to enoxaparin 30 mg twice daily Safety Similar bleeding compared to enoxaparin 40 mg daily Less bleeding compared to enoxaparin 30 mg twice daily New Engl J Med 2009;361: Lancet 2010;375: New Engl J Med 2010;363:
53 Acute Coronary Syndrome
54 Apixaban Acute Coronary Syndrome (APPRAISE 2) Double blind, placebo controlled, RCT ACS plus 2 additional risk factors Apixaban 5 mg twice dil daily 2.5 mg twice daily (CrCl < 40 ml/min) No benefit in any efficacy outcomes Safety Major & minor TIMI, ISTH, and GUSTO criteria bleeding was increased with apixaban Increased fatal and intracranial bleeding Study terminated early at 1 year New Engl J Med 2011;365:
55 Rivaroxaban ATLAS ACS ACS 2 TIMI 51 Trial is ongoing All patients received low dose ASA with either: Rivaroxaban2.5 25mg twice dil daily or Rivaroxaban 5 mg twice daily Groups were stratified based on clopidogrel use Results expected in November Am Heart J 2011;161:
56 Additional Developing Information apixabanaban is currently being ealatedfor evaluated VTE prophylaxis in medical patients An additional factor Xa inhibitor (edoxaban) is currently in phase 3 clinical trials Afib VTE treatment
57 Dabigatran Patient Information Store in original container Discard opened product after 60 days Dyspepsia most common side effect (15%) Do not open capsule Rivaroxaban Ask pharmacist or physician about DDIs Do not crush, chew, or split tablet Overall tolerated well
58 Which of the following best describes your opinion regarding prescribing of dabigatran (Pradaxa ) or rivaroxaban (Xarelto ) after this program? 1. I will begin routinely prescribing these agents. 2. I may prescribe them in a limited and select group of patients. 3. I am still very hesitant to prescribe them. 4. I will not prescribe them at all for now. I will begin r... 0% 0% 0% 0% I may prescrib... I am still ver... I will not pre...
59 Summary Table Parameter Apixaban Dabigatran Rivaroxaban Target Protein Factor Xa Thrombin (IIa) Factor Xa Pro Drug No Yes (etexilate) No 1 Elimination CYP3A4/P gp Renal CYP3A4/P gp Renal Adjustment Avoid < 15 ml/min 15 29ml/min Avoid < 30 ml/min Avoid < 15 ml/min Drug Drug Interact. CYP3A4/P gp Rifampin (P gp) CYP3A4/P gp Onset of activity 3 4 hrs 1 2 hrs 2 4 hrs t½ 8 15 hrs hrs 5 9hrs Dosing interval Twice daily Twice daily Daily Monitoring tests Anti factor Xa ECT, TT, +/ aptt Anti factor Xa FDA Indications None Non valvular Afib. Ortho VTE Proph. Clinical Uses Afib Afib, VTE Afib, Ortho VTE Proph, VTE
60 David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationUpdate with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist
Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist Peter Thomson, Pharm D. Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Clinical
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationAnticoagulation in 2014: Using the New Agents Safely
Anticoagulation in 2014: Using the New Agents Safely Tracy Minichiello, M.D. Professor of Medicine University of California, San Francisco Chief, SF VA Anticoagulation & Thrombosis Service Disclosures
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAre the days of Warfarin numbered?
2 nd SAVTE Symposium Are the days of Warfarin numbered? YES Dr. Mohamed A. Abdelaal, MD, FRCPath, FRCPI Consultant Haematologist King Abdulaziz Medical City - Jeddah, Saudi Arabia 1 3 May 2012, Casablanca,
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationTrue/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationDabigatran 101: Community Pharmacists. Peter Thomson Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority
Dabigatran 101: Community Pharmacists. Peter Thomson Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Objectives At the end of this session, you should be able to: Describe
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationNovel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationVENOUS THROMBOEMBOLISM PHARMACOLOGY. University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D
VENOUS THROMBOEMBOLISM PHARMACOLOGY University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D LEARNING OBJECTIVES Know what factors anticoagulant medications
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationDiscuss the role of idarucizumab for the management of bleeding associated with dabigatran
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationAcute Care: Understanding Direct Oral Anticoagulants (DOACs)
Acute Care: Understanding Direct Oral Anticoagulants (DOACs) National Conference for Nurse Practitioners (NCNP) October 11, 2017 John Togami, PharmD, PhC Pharmacist Clinician - Outpatient Anticoagulation
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationNew drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle
New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle CONCLUSIONS 1. Arrival of new anticoagulants is a Good Thing. CONCLUSIONS 1. Arrival of new anticoagulants
More informationAfter acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationAbbreviated Class Update: Anticoagulants, oral and parenteral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationArrhythmias and Clinical EP Contemporary Management of Anticoagulant Therapies
Arrhythmias and Clinical EP Contemporary Management of Anticoagulant Therapies Samuel Asirvatham, MD & Ivan Mendoza, MD Saturday, June 24, 2017 11:15 a.m. to 12 p.m. Disclosures Relevant financial relationship(s)
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationJoost van Veen Consultant Haematologist
Joost van Veen Consultant Haematologist Bridging anticoagulation - conclusion Aim Questions What is the evidence? Does oral anticoagulation need to be stopped and if so when? When and at what dose is alternative
More information